Transgenic Mouse Model for Alzheimer's Disease Pathology
Solution Overview
Problem
Current mouse models for Alzheimer's Disease do not fully recapitulate the human pathology, lacking robust amyloid plaques, neurofibrillary tangles, and neuronal loss, which are essential for replicating the cognitive deficits observed in Alzheimer's patients.
Innovation Solution
The creation of modified non-human warm-blooded vertebrate animals, such as mice, that express a biologically active human APP polypeptide and have reduced inducible Nitric Oxide Synthase (iNOS) protein function, which results in the development of amyloid plaques, neurofibrillary tangles, and significant neuronal loss, mimicking the human Alzheimer's Disease pathology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current mouse models are used for Alzheimer's Disease research, then the models are simple to maintain and operate, but they fail to fully recapitulate human pathology including robust amyloid plaques, neurofibrillary tangles, and neuronal loss
Solution Approach 1:
The patent applies segmentation by creating distinct genetic modifications in separate stages: first introducing human APP transgenes to generate amyloid plaques, then introducing tau transgenes to generate neurofibrillary tangles, and finally combining with NOS2 knockout to enhance neuronal loss. This modular approach allows each pathological feature to be independently controlled and optimized, resulting in a comprehensive model that fully recapitulates human Alzheimer's pathology while maintaining manageable experimental complexity through systematic breakdown of the modeling process
Solution Approach 2:
The patent creates a composite animal model by combining multiple genetic elements (human APP transgenes, human tau transgenes, and NOS2 knockout) into a single organism. This composite approach integrates different pathological features that individually exist in separate mouse models, producing a unified model system that exhibits all three hallmarks of human Alzheimer's disease: amyloid plaques, neurofibrillary tangles, and neuronal loss, thereby significantly improving pathology recapitulation accuracy
2Reliability
If modified mice with reduced iNOS function are created to develop full Alzheimer's pathology, then robust amyloid plaques and neurofibrillary tangles are produced, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies preliminary action by first establishing well-characterized parental lines with specific genetic modifications (APP transgenic mice and NOS2 knockout mice) before combining them to create the final model. This preliminary development of component strains with defined phenotypes allows for systematic breeding and validation, making the overall manufacturing process more controllable and reproducible despite the complexity of generating multiple transgenic lines
Solution Approach 2:
The patent utilizes parameter changes by modifying specific genetic parameters (introducing human APP and tau transgenes, knocking out NOS2) to achieve desired pathological outcomes. By systematically altering these genetic parameters in controlled combinations, the patent generates robust pathology while maintaining ease of manufacture through standardized genetic manipulation protocols and selective breeding strategies
3Reliability
If multiple transgenic modifications are introduced to achieve full pathology, then the model accurately reflects human Alzheimer's disease, but the time and resources required for model development increase
Solution Approach 1:
The patent segments the model development into distinct phases: Phase 1 involves generating APP transgenic mice to establish amyloid plaque formation; Phase 2 introduces tau transgenes to develop neurofibrillary tangles; Phase 3 combines with NOS2 knockout to enhance neuronal loss. This segmentation allows parallel development of component lines and systematic validation at each stage, reducing overall development time while maintaining high disease model accuracy through incremental complexity addition
Solution Approach 2:
The patent achieves universality by creating a multi-functional animal model that simultaneously exhibits multiple pathological features (amyloid plaques, neurofibrillary tangles, neuronal loss) and behavioral deficits relevant to human Alzheimer's disease. This universal model can be used for diverse research applications including drug screening, pathology studies, and behavioral analysis, thereby justifying the increased development time and resources through its broad utility and high accuracy in reflecting human disease
Data Source
AI summary
A modified non-human warm-blooded vertebrate animal in which a biologically active human APP polypeptide is expressed, and in which function of its inducible Nitric Oxide Synthase (iNOS) protein is reduced as compared to a non-modified animal, methods of making the animal, and methods of testing a candidate composition for activity in the treatment of Alzheimer's Disease using the animal.